CIM22LAPP1A-11 is an intermediate-maturing, high-yielding, white maize hybrid with resistance to TSC, MLB and ear rots. The product is notable for its high rainfed yield, excellent female parent seed yield, dent grain and resistance to root and stalk lodging and is suitable for food use in tropical, rainfed, low-altitude areas in Latin America. |
|
General Information |
|
Target Region |
Latin America |
|
Adaptation/Agroecological zone |
0 - 1200m above sea level |
|
Type of product |
Three-way hybrid |
|
Year first announced |
2024 |
|
|
|
|
Grain Characteristics |
|
Grain color |
White |
|
|
|
Grain texture |
Dent |
Abiotic Stress Performance |
|
|
|
Grain yield under optimum conditions |
8.70 t/ha |
|
Biotic Stress Performance |
Grain yield under rainfed conditions |
5.11 t/ha |
|
Maydis leaf blight (MLB) (1-9)* |
2.7 |
Grain yield on-farm (avg) |
7.07 t/ha |
|
Tar Spot Complex (TSC) (1-9)* |
3.2 |
Grain yield on-farm (opt.) |
8.73 t/ha |
|
Ear Rots (%) |
6.9% |
Grain yield on-farm (rainfed) |
5.54 t/ha |
|
*Scored on 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible |
|
|
|
Agronomic Characteristics |
|
|
|
Maturity group |
Intermediate |
|
Seed Production Characteristics |
50% anthesis |
58 DAP |
|
SC female parent seed yield |
8.8 t/ha |
Plant height |
241 cm |
|
Male seed yield |
4.5 t/ha |
Ear height |
126 cm |
|
Nicking |
-5 days |
Ear position (ratio) |
0.52 |
|
|
|
Ears per plant |
1.03 |
|
Comments |
Ear aspect (1-9)* |
4.3 |
|
Product information is based on data from the 2022 CIMMYT LatAm Stage 4 Regional Trials and 2023 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.
Abbreviations:
DAP = days after planting
SC = Single-cross
MLB = Maydis leaf blight
TSC = Tar spot complex |
Plant aspect (1-9)* |
4.9 |
|
Bad husk cover |
4.4% |
|
Root lodging |
3.1% |
|
Stalk lodging |
7,1% |
|
Anther-silking interval |
0.6 days |
|
*Plant and ear aspects are scored on 1-9 scale, where 1 = desirable and 9 = undesirable characteristics |
|
|
|
|
|
Further Links |
|
Full Announcement & trial data |
|
|